Moderna Files COVID-19 Vaccine After Second Impressive Read-Out

Does It Have Edge In Preventing Severe Cases?

Second read-out maintains 94% level of efficacy, with a very early signal that it could outperform Pfizer’s rival mRNA candidate in preventing severe cases.

Moderna's laboratories, where it began its collaboration with the NIH on its vaccine in January 2020. • Source: Moderna

Moderna, Inc. has submitted its dossier to the US Food and Drug Administration and is ready to file with other regulators for its COVID-19 vaccine candidate MRNA-1273 after unveiling a second impressive efficacy readout from the Phase III COVE study.

The latest readout bolsters hopes that the first emergency use approvals (EUAs) can come within weeks, releasing the first millions of doses before the end of 2020 to turn the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from COVID-19

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By 

One Phase III trial hits but a second study misses by a mile.

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By 

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Arcturus and CSL Take on Pfizer With Longer-Lasting COVID Vaccine

 
• By 

Kostaive is the first self-amplifying mRNA COVID-19 vaccine to receive approval from the European Commission and could provide serious competition to Pfizer/BioNTech's Comirnaty and Moderna's Spikevax.

Under-Pressure Moderna Banks $590m To Speed Up Bird Flu Vaccine

 
• By 

A week after a downbeat forecast at J.P. Morgan Healthcare Conference, the US mRNA specialist has pocketed another sizeable sum from the US Department of Health and Human Services to accelerate development of an H5N1 mRNA pandemic influenza vaccine.

More from Scrip

Quotables: Pharma Leaders On The Month’s Hot Topics

 

The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III

 

Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.

Astellas Gets CLDN.18.2-Targeted ADC From China’s Evopoint

 
• By 

Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.